Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
F17 dengue vaccine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
F17 is a tetravalent live-attenuated dengue vaccine (TLAV) candidate developed by the U.S. Army Medical Research and Development Command (USAMRDC), specifically the Walter Reed Army Institute of Research (WRAIR), in collaboration with GSK. The vaccine is designed to provide protection against all four dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4). The "F17" designation refers to a specific formulation ratio of the four attenuated virus strains, optimized to ensure a balanced immune response and reduce the risk of interference between serotypes. It works by mimicking a natural infection to stimulate the production of neutralizing antibodies and cellular immune responses without causing the disease itself. Clinical trials, including Phase I/II studies in Thailand, have evaluated its safety and immunogenicity in both flavivirus-naïve and flavivirus-experienced populations, particularly children.
- Other names
- USAMRDC tetravalent live-attenuated dengue vaccineWRAIR dengue vaccineWRAIR/GSK dengue vaccinedengue vaccine formulation 17-U.S. Army Medical Research and Development Command-dengue
Beyond the preview
Go deeper on F17 dengue vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on F17 dengue vaccine.